Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Acquiring Nexcelom Bioscience for $260M

NEW YORK – PerkinElmer announced after the close of the market on Wednesday it has reached a deal to acquire Nexcelom Bioscience for $260 million in cash.

The acquisition is expected to close in the second quarter.

Based in Lawrence, Massachusetts, Nexcelom provides tools and instruments for cell counting and analysis, including automated cell counting instruments, image cytometry workstations, assays, cell reagents and other consumables.

The company also provides fit-for-purpose cell counting method selection and development instruments that follow ISO cell counting standards and aid in developing cell, gene, and immune-oncology therapies; virology drugs; and vaccines. The company was founded in 2003 and has about 130 employees in the US, UK, and China, and it expects 2021 revenues of about $40 million, PerkinElmer said.

Nexcelom's capabilities in drug development, combined with PerkinElmer's drug discovery solutions, "will expand our efforts to help academic, government, and biopharmaceutical organizations streamline their complete workflows and support efforts to accelerate time to target and time to market for novel therapies," PerkinElmer CEO Prahlad Singh said in a statement.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.